Rani Therapeutics Holdings, Inc.
RANI
$1.10
$0.00010.01%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -6.28% | -15.19% | -11.08% | -5.23% | -17.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.65% | -33.92% | -31.54% | -15.03% | -23.16% |
| Operating Income | 16.30% | 33.92% | 31.54% | 15.03% | 23.16% |
| Income Before Tax | -11.86% | 30.60% | 28.41% | 12.20% | 19.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.86% | 30.60% | 28.41% | 12.20% | 18.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -2.62% | -34.99% | -29.96% | -13.76% | -18.69% |
| Net Income | -26.05% | 26.25% | 26.85% | 10.62% | 19.21% |
| EBIT | 16.30% | 33.92% | 31.54% | 15.03% | 23.16% |
| EBITDA | 16.88% | 34.57% | 32.23% | 15.57% | 23.69% |
| EPS Basic | 0.22% | 34.65% | 29.58% | 13.36% | 22.23% |
| Normalized Basic EPS | 68.41% | 23.21% | 24.97% | 8.58% | 23.84% |
| EPS Diluted | 0.22% | 34.65% | 29.58% | 13.36% | 22.23% |
| Normalized Diluted EPS | 68.41% | 23.21% | 24.97% | 8.58% | 23.84% |
| Average Basic Shares Outstanding | 26.35% | 12.85% | 3.86% | 3.15% | 3.87% |
| Average Diluted Shares Outstanding | 26.35% | 12.85% | 3.86% | 3.15% | 3.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |